Remedium Capital Partners
Latest statistics and disclosures from Remedium Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ORKA, SYRE, APGE, DMRA, JBIO, and represent 98.56% of Remedium Capital Partners's stock portfolio.
- Added to shares of these 3 stocks: CBIO (+$6.5M), SYRE, APGE.
- Started 1 new stock position in CBIO.
- Reduced shares in these 1 stock: Crescent Biopharma (-$6.6M).
- Sold out of its position in Crescent Biopharma.
- Remedium Capital Partners was a net buyer of stock by $983k.
- Remedium Capital Partners has $452M in assets under management (AUM), dropping by 60.64%.
- Central Index Key (CIK): 0002104501
Tip: Access up to 7 years of quarterly data
Positions held by Remedium Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Remedium Capital Partners
Remedium Capital Partners holds 6 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Oruka Therapeutics (ORKA) | 33.0 | $149M | 1.6M | 95.17 |
|
|
| Aeglea Biotherapeutics (SYRE) | 28.8 | $130M | 1.5M | 88.78 |
|
|
| Apogee Therapeutics (APGE) | 17.2 | $78M | 587k | 132.73 |
|
|
| Galecto (DMRA) | 11.8 | $53M | 2.0M | 26.01 |
|
|
| Jade Biosciences (JBIO) | 7.8 | $35M | 1.6M | 22.22 |
|
|
| Crescent Biopharma (CBIO) | 1.4 | $6.5M | NEW | 361k | 18.00 |
|
Past Filings by Remedium Capital Partners
SEC 13F filings are viewable for Remedium Capital Partners going back to 2026
- Remedium Capital Partners 2026 Q2 filed Aug. 7, 2026
- Remedium Capital Partners 2026 Q1 restated filed May 19, 2026
- Remedium Capital Partners 2026 Q1 filed May 13, 2026